New Clinical Trial Results Introduced in the Q3 2025 Transthyretin Cardiomyopathy/ATTR/hATTR Market

Within the Q3 2025 transthyretin cardiomyopathy/ATTR/hATTR market, companies used visual campaigns to promote the efficacy, safety, dosing, mechanism of action, and assistance programs for their respective brands. One corporation also announced new clinical trial results, which were showcased at conferences.

The HCP “Knockdown” and DTC “Ticket” campaigns advertised Amvuttra’s efficacy and safety results from the HELIOS-B study, treatment benefits, mechanism of action, and Alnylam Assist program. Alnylam also discussed its Q2 2025 financial results, leadership in the transthyretin amyloidosis market, and pipeline.

BridgeBio announced new ATTRibute-CM results, which were presented at two conferences. The DTC “Raise Your Expectations” campaign was also featured as materials promoted Attruby’s efficacy, safety, dosing, Forging Bridges program, and availability on the VA formulary and through specialty pharmacies.

AstraZeneca and Ionis touted Wainua’s efficacy, safety, dosing, Wainua Way program, and the Amyloidosis Support Group foundation. The HCP “Stop/Start” and “See the PATTRNS” visual themes were also utilized.